Navigation Links
Pioneer(R) Surgical Technology's NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study
Date:10/30/2008

ioneer Orthobiologics is developing a rich pipeline of products indicated for a variety of spinal and orthopaedic applications. Pioneer focuses on developing products which are easier and faster for the surgeon, cost effective for the health care system, and provide better patient outcomes.


'/>"/>
SOURCE Pioneer Surgical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pioneer(R) Surgical Technology Announces the Market Release of its Cross-Fuse(TM) Lateral Vertebral Body Replacement (VBR) System
2. Pioneer(R) Surgical Technology Introduces the BacJac(TM) Interspinous Decompression System to the European Spine Market
3. Pioneer(R) Surgical Technology, Inc. Continues to Prove Science Behind PEEK-on-PEEK(TM) Technology for Motion Preservation Devices
4. Many Breast Cancer Patients Are Not Receiving Most Advanced Breast Conserving Surgical Techniques, New Study Finds
5. STAAR Surgical Reports 33% Third Quarter Revenue Growth
6. New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery
7. An analysis of the surgical and perioperative complications in right hepatectomies
8. Surgical technique halts cell loss, Parkinsons researchers find
9. Dr. Lisa Zdinak Announces, CO2TouchTM Brazilian Carboxytherapy - New Technology for Non-Surgical Treatment of Stretch Marks, Cellulite and Dark Undereye Circles
10. Older Adults Reluctant to Question Surgical Treatment
11. Study shows that surgical weight loss does not eliminate obstructive sleep apnea
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 1Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 2Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 3Herley Industries Inc Reports Third Quarter Earnings 48677 1Herley Industries Inc Reports Third Quarter Earnings 48677 2Herley Industries Inc Reports Third Quarter Earnings 48677 3Herley Industries Inc Reports Third Quarter Earnings 48677 4Herley Industries Inc Reports Third Quarter Earnings 48677 5Herley Industries Inc Reports Third Quarter Earnings 48677 6Herley Industries Inc Reports Third Quarter Earnings 48677 7Herley Industries Inc Reports Third Quarter Earnings 48677 8Herley Industries Inc Reports Third Quarter Earnings 48677 9Herley Industries Inc Reports Third Quarter Earnings 48677 10Herley Industries Inc Reports Third Quarter Earnings 48677 11Herley Industries Inc Reports Third Quarter Earnings 48677 12Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 1Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 2